Browse

Eli Lilly is moving its triple-agonist drug retatrutide closer to a potential launch for sleep-apnea. The company, which expects to introduce the drug for obesity next year, is now gathering data i…

After a quarter century of work, the German biotech Immatics is facing a pivotal moment as it awaits Phase 3 results for its lead candidate in melanoma.

“As measles outbreaks spread in the U.S., it may be time to learn how other countries get their outbreaks under control,” writes Raj Panjabi.